The Rapamycin Dosing Debate: What PEARL Tested, the Bioavailability Problem, and What Is Unproven

Does rapamycin extend human lifespan?

Rapamycin is an FDA-approved prescription drug (Rapamune, sirolimus). It is labeled to prevent kidney transplant rejection and to treat a rare lung disease called lymphangioleiomyomatosis. It is not approved for aging, and every dosing schedule below is either what a study did or someone's opinion. That matters, because rapamycin may be the most argued-about molecule in longevity. It has the best animal lifespan results of any drug, a loud community of people testing it on themselves, and so little evidence in people that it fits in one article. This is that article.

What did the PEARL trial actually test?

PEARL (short for Participatory Evaluation of Aging and Rapamycin for Longevity) was run from people's homes, compared with a dummy pill, with nobody knowing who got what. It was paid for mostly by crowdfunding through Lifespan.io and run by AgelessRx, an online clinic that prescribes rapamycin. Seven authors work for the company and own shares in it, which the paper says openly. That is unusual and worth knowing. The published paper reports that belly fat, measured by a DXA body scan and chosen as the main goal in advance, did not change in any group. Serious side effects: 1 in the 10 mg group, 2 in the 5 mg group and 3 on the dummy pill. Minor side effects were also similar, with one exception. Stomach problems were reported by 8 people on 10 mg, 7 on 5 mg and 4 on the dummy pill.

The lean mass result is the one that gets quoted. It comes from one small group (women, top dose) in a study of 114 people. Results like that need repeating before they mean anything, and the authors say so. The result that should get quoted more is that the main goal failed. A year of weekly rapamycin did not move belly fat, the thing the researchers picked in advance to measure.

Why is compounded rapamycin only about 31 percent bioavailable?

This finding came from the same research group that ran PEARL, and it changes how to read the study. PEARL used pharmacy-made rapamycin, and the blood-level paper says that product reached roughly one third of the blood level of the brand-name one. In blood-level terms, PEARL's 10 mg group was more like 3 mg of the brand-name drug, and the 5 mg group like less than 2 mg. That may explain the clean safety record as much as anything about weekly dosing. It also means 'X mg a week' claims from different sources can't be compared unless you know which product they used. The paper also looked at 316 users in a database. Blood levels peaked around day 2 and then fell slowly, which fits with how long the drug stays in the body (its half-life).

What does the 333-person user survey show?

The survey is the biggest picture of how people use rapamycin for longevity, and it is honest about its limits. People chose whether to answer. People who quit because of side effects were less likely to reply. And users rated their own health, happiness and thinking better by more than 3 to 1, which is exactly what you'd expect from people who chose to keep taking something. The mouth health follow-up found that how often mouth ulcers happened had nothing to do with the dose, the gap between doses or how long people had taken it. Bad ulcers were rare. Several authors of both survey papers work for or own shares in AgelessRx, the company that ran PEARL, which the papers say openly.

Why weekly? Blagosklonny's reasoning

The article is where nearly every weekly schedule comes from. Its logic goes like this. Daily rapamycin in transplant patients causes well-known side effects: mouth sores, higher blood fats, blood sugar trouble and slow wound healing. Those come partly from blocking mTORC2 for a long time. A pulse schedule, with the same total dose spread further apart, might keep the benefit and lose the cost. Blagosklonny also argued rapamycin should be started before disease, not after. Readers should hold two things at once. The reasoning makes sense and is widely accepted in the field. And it has never been tested against daily dosing in a study of aging in people. He himself called longer human life a prediction from mouse data, not a proven fact.

What the mouse data show, and what they do not

The mouse results are why anyone takes this drug. In 2009, the US National Institute on Aging's Interventions Testing Program (ITP) reported in Nature that rapamycin at 14 ppm in food made mixed-breed mice live longer at three separate test sites. It was started at 600 days old, roughly 60 in human years. Lifespan rose 14 percent in females and 9 percent in males, measured when 90 percent had died. In 2014, the same program reported in Aging Cell that a dose three times higher, 42 ppm, raised typical lifespan 23 percent in males and 26 percent in females. Females gained more at every dose, maybe because female mice reach higher blood levels. It is the only drug the ITP has found that lengthens mouse life strongly and again and again.

Here is what the mouse results can't tell you. Whether a weekly human dose, at a fraction of what the mice got, does anything for human aging. Whether the mouse benefit, which comes partly from delaying cancer deaths, carries over to a species that gets different cancers. And whether lean mass in 35 women over a year stands for anything bigger. The study in people that would answer the lifespan question would need thousands of people and decades, and nobody has paid for one. So: lifespan in mice, strong and repeated. Safety in people over one year, moderate. Aging results in people, none.

The bottom line

The rapamycin debate is often framed as 'what dose'. The honest answer is that the studies in people so far asked 'is it safe for a year', and got a reassuring answer using a pharmacy-made product that delivered a third of the expected drug. Whether any schedule slows human aging is unproven as of September 2026. Rapamycin is a prescription drug that weakens the immune system, and using it off-label is a decision for a doctor and patient, with the study details above in front of them.